- Clone:
- REA412 | 31G4D8
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC Glossary
- Select a conjugate:
- Select a size:
Related products for LT-βR Antibody, anti-human, REAfinity™
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Cells were incubated with an excess of purified unconjugated LT-βR (REA412) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.
To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.
Overlay histogram showing flow cytometric analysis of LT-ßR knockout cells. Wild type (red) and knockout cells (blue) were stained with LT-ßR-PE, clone (REA412). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
Clone REA412 recognizes the human lymphotoxin beta receptor (LT-ßR) antigen, a 47 kDa single-pass type I membrane protein which is also known as tumor necrosis factor receptor superfamily member 3 (TNF-RIII). LT-ßR is a member of the TNF receptor family that play a role in the development and organization of lymphoid tissues. Unlike the other TNF receptors, LT-ßR does not bind a soluble ligand, but rather, a membrane form of a heterotrimeric lymphotoxin complex comprised of one LTα and two LTβ molecules. The development of lymph nodes is a process that involves the LT-ßR dependent crosstalk between mesenchymal lymphoid tissue organizer and hematopoietic lymphoid tissue inducer cells. Cell death induced by LT-ßR is dependent on TRAF3, whereas NFκB activation appears to be mediated by TRAF5 or TRAF2. LT-ßR is expressed on a variety of human primary and transformed cells, but is absent on T or B lymphocytes and primary monocytes or peripheral dendritic cells, although LT-ßR is detected on some myeloid leukemic lines. In the developing thymus LT-ßR is prominent along the trabeculae and into the medulla up to corticomedullary junction. In the spleen, LT-ßR is prominently expressed by cells in the red pulp and along the borders of red and white pulp which colocalizes with reticular stromal cells.
Additional information: Clone REA412 displays negligible binding to Fc receptors.
TNF-RIII, LTBR, D12S370, LT-BETA-R, TNF-RII, CD18, TNFR-RP, TNFR2-RP, TNFR3, TNFCR
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Rooney, I. A. et al. (2000) The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J. Biol. Chem. 275 (19): 14307-14315
- Onder, L. et al. (2013) Endothelial cell-specific lymphotoxin-β receptor signaling is critical for lymph node and high endothelial venule formation. J. Exp. Med. 210 (3): 465-473
- Crowe, P. D. et al. (1994) A lymphotoxin-beta-specific receptor. Science 264 (5159): 707-710